Literature DB >> 25372848

A combination of ledipasvir and sofosbuvir (Harvoni) for hepatitis C.

.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25372848

Source DB:  PubMed          Journal:  Med Lett Drugs Ther        ISSN: 0025-732X            Impact factor:   1.909


× No keyword cloud information.
  4 in total

1.  Economic and Public Health Impacts of Policies Restricting Access to Hepatitis C Treatment for Medicaid Patients.

Authors:  Alexis P Chidi; Cindy L Bryce; Julie M Donohue; Michael J Fine; Douglas P Landsittel; Larissa Myaskovsky; Shari S Rogal; Galen E Switzer; Allan Tsung; Kenneth J Smith
Journal:  Value Health       Date:  2016-03-24       Impact factor: 5.725

2.  Discovery of the 2-phenyl-4,5,6,7-Tetrahydro-1H-indole as a novel anti-hepatitis C virus targeting scaffold.

Authors:  Ivan A Andreev; Dinesh Manvar; Maria Letizia Barreca; Dmitry S Belov; Amartya Basu; Noreena L Sweeney; Nina K Ratmanova; Evgeny R Lukyanenko; Giuseppe Manfroni; Violetta Cecchetti; David N Frick; Andrea Altieri; Neerja Kaushik-Basu; Alexander V Kurkin
Journal:  Eur J Med Chem       Date:  2015-04-10       Impact factor: 6.514

3.  An Unexpected Interaction between Sofosbuvir/Ledipasvir and Atorvastatin and Colchicine Causing Rhabdomyolysis in a Patient with Impaired Renal Function.

Authors:  Shyam Patel; Jennifer Andres; Kamran Qureshi
Journal:  Case Rep Med       Date:  2016-08-22

Review 4.  Interferon-Free Treatments for Chronic Hepatitis C Genotype 1 Infection.

Authors:  Alireza FakhriRavari; Mazyar Malakouti; Rebecca Brady
Journal:  J Clin Transl Hepatol       Date:  2016-06-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.